Bernard Cambou

Biography

 Prior to joining Targazyme, Dr. Cambou, PhD. was a strategic advisor to the biopharmaceutical industry and Owner & Managing Partner of US-based Bernard Cambou Bio Consulting (BC2). BC2 is specialized in transactional and operational endeavors both in the USA and Europe.  From January 2007 until May 2010, Dr. Cambou was Chief Executive Officer of Cytomics Pharmaceuticals, a France-based oncology company involved into novel, small molecule targeted therapy approaches to treat cancer.  From 2002 to 2006, Dr. Cambou was a Venture Capital Partner with Birchmere Ventures, a Life Sciences Investment firm based in Pittsburgh, PA and co-managed with San Francisco-based Bay City Capital. Concurrent to Birchmere Ventures, from 2005 to December 2006, Bernard was Acting Chief Executive Officer of Pennsylvania-based Cellatope Inc. a biomarker/molecular diagnostics company which he co-founded with two clinicians from the University of Pittsburgh Medical Center and remained a Board member/investor. Cellatope was acquired by Cypress Biosciences (Nasdaq: CYPB) in February 2009. Prior to Birchmere Ventures, Dr. Cambou was Vice President, Business Development with Human Genome Sciences. He joined HGS in 2000 after they acquired Principia Pharmaceuticals, a VC-funded spin-off from Aventis, which he co-founded in 1999. Prior to that, Bernard held various research and business development positions with Aventis in France, Japan and the United States where he relocated in 1995. Dr. Cambou, who holds an engineering degree in agronomy/microbiology, is a post-graduate from the Pasteur Institute (Masters of Science degree) and the University of Technology of Compiègne (Masters of Science and Doctoral degrees). In the early 80s, he spent two and a half years at the Massachusetts Institute of Technology, Cambridge, MA as a post-doctoral fellow. He also holds an Executive Master of Business Administration degree from ESSEC, Paris.  

Research Interest

 Business Stratergy